Inhibikase director granted options on 155K shares

Inhibikase Therapeutics director Dennis N. Berman received a stock option grant covering 155,000 shares of common stock.

Rhea-AI Filing Summary

Inhibikase Therapeutics director Dennis N. Berman received a stock option grant covering 155,000 shares of common stock. The option has an exercise price of $1.91 per share and expires on June 26, 2036.

The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to his continued service as a director through that date. After this grant, Berman holds stock options for 155,000 underlying shares directly.

Insider Trade Summary

Grant/Award: 155,000 shares

Grant/Award 1 txn

Insider BERMAN DENNIS N

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	155,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 155,000 contracts (Direct)

Footnotes (1)

1. F1. The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Key Figures

Option grant size: 155,000 shares Exercise price: $1.91 per share Expiration date: June 26, 2036 +3 more

6 metrics

Option grant size 155,000 shares Stock Option (Right to Buy) granted to director

Exercise price $1.91 per share Conversion or exercise price of granted options

Expiration date June 26, 2036 Option term end date

Vesting date June 26, 2027 Latest possible vesting date, subject to earlier meeting-based vesting

Total options after grant 155,000 shares Total option-based holdings following this transaction

Transaction date June 26, 2026 Date of stock option grant

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, annual meeting of stockholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 1.9100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-26T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of stockholders financial

"the day prior to the next annual meeting of stockholders"

vesting financial

"The options will vest on the earlier of June 26, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Inhibikase Therapeutics (IKT) director Dennis Berman report on this Form 4?

Dennis N. Berman reported receiving a grant of stock options covering 155,000 shares of Inhibikase Therapeutics common stock. These options were awarded as compensation and are not an open-market purchase or sale of existing shares.

What are the key terms of Dennis Berman’s new Inhibikase (IKT) stock options?

The granted options cover 155,000 shares of common stock with an exercise price of $1.91 per share. They expire on June 26, 2036, giving the director a long-term right to buy shares at that fixed price.

When do Dennis Berman’s Inhibikase (IKT) options vest?

The options vest on the earlier of June 26, 2027 or the day before Inhibikase’s next annual meeting of stockholders. Vesting is conditioned on Berman continuing to serve as a director through the applicable vesting date.

Is this Inhibikase (IKT) Form 4 a stock purchase or sale by Dennis Berman?

No, this Form 4 reflects a grant of stock options as compensation, not a market purchase or sale. Berman did not buy or sell existing shares; he received the right to buy shares later at a $1.91 exercise price.

How many Inhibikase (IKT) option shares does Dennis Berman hold after this grant?

Following this transaction, Dennis Berman holds stock options representing 155,000 shares of Inhibikase common stock. This reflects the full size of the newly granted award reported in this Form 4 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/30/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BERMAN DENNIS N

(Last) (First) (Middle)

1000 N. WEST STREET, SUITE 1200

(Street)

WILMINGTON DELAWARE 19801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.91	06/26/2026		A		155,000		(1)	06/26/2036	Common Stock	155,000	$0	155,000	D

Explanation of Responses:

1. The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

	/s/ Mark Iwicki, attorney-in-fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)